The U.S. FDA has approved Revolution Medicinesâ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new âhope to those with the deadly cancer. The once-daily pill, to be called Rasonque, was approved for metastatic âpancreatic cancer in patients who have received prior treatment or cannot receive combination chemotherapy. The drug is designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers. Revolution said the drug is now available in the U.S. at âa price of $39,800 for a 30-day supply, with eligible commercially insured patients potentially paying as little as $0 with co-pay assistance. When Revolution âannounced the trial results in April for the drug, it set off a firestorm of demand. â The FDA quickly granted early access to it under its compassionate use program, which allows patients with serious or life-threatening conditions âto get experimental treatments outside clinical trials prior to authorization by the regulator. The experimental cancer drug extending Ben Sasseâs life The treatment has already offered some p
Aug 26, 2026 → Aug 26, 2026
The U.S. FDA has approved Revolution Medicinesâ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new âhope to those with the deadly…
Read original at CNN →1 updates from 1 source.
The U.S. FDA has approved Revolution Medicinesâ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new âhope to those…
Read original at CNN →What this story stands on. Tier 0 is a primary record or the subject's own words; higher tiers must be attributed, never stated as bare fact.
The U.S. FDA has approved Revolution Medicines’ groundbreaking pancreatic cancer drug after it was shown to double the survival rate of patients with advanced disease in a large trial, offering new hope to those with the deadly cancer.…
View source →Tier key: T0 = Primary source · T1 = Wire · T2 = Outlet report · T3 = Commentary
It takes a long time to build new nuclear plants. So, some U. S. companies are looking to get more electricity out of reactors that already exist.
The world’s most swoon-worthy train trips, from the rugged Peruvian highlands to the romantic Canadian Rockies.
Pimco Economist Tiffany Wilding discusses findings of the firm’s annual cyclical outlook. The report points to the key buffers for the US economy, booming investment in AI, the…
China’s booming artificial intelligence sector has given local researchers good reason to remain in the country, but it has yet to lure overseas scientists despite a government…
President Donald Trump signaled that his appetite to ban exports of US diesel has cooled given the risk of unintended price spikes, and one of his top deputies indicated Europe…
American AI companies’ performance lead over China narrowed sharply in past months to a record low after labs such as DeepSeek gained ground, threatening US tech supremacy,…
